{"DataElement":{"publicId":"2899563","version":"1","preferredName":"Histologically Confirmation Prostate Adenocarcinoma Diagnosis Prior Randomization Ind-2","preferredDefinition":"the yes/no indicator that asks whether the patient has histologically confirmed adenocarcinoma of the prostate, diagnosed prior to randomization.","longName":"H_C_PA_DX_P_RND_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2899334","version":"1","preferredName":"Histologically Confirmation Prostate Adenocarcinoma Diagnosis Prior Randomization","preferredDefinition":"information relating to histologically (involving the use of histology or histological techniques) confirmed (having been established or verified) adenocarcinoma of the prostate (one of the most common malignant tumors afflicting men, the majority of which arise in the peripheral zone of the prostate gland) diagnosed (the investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms) prior to randomization.","longName":"H_C_PA_DX_PRIOR_RNDM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2899281","version":"1","preferredName":"Histologically Confirmed Prostate Adenocarcinoma  Diagnosis","preferredDefinition":"Involving the use of histology or histological techniques.:Confirmed; having been established or verified.:Prostate adenocarcinoma is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. --2002:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"C25527:C25458:C2919:C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologically","conceptCode":"C25527","definition":"Involving the use of histology or histological techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prostate Adenocarcinoma","conceptCode":"C2919","definition":"An adenocarcinoma arising from the prostate gland.  It is one of the most common malignant tumors afflicting men.  The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland.  Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival.  Several grading systems have been proposed, of which the Gleason system is the most commonly used.  Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BEDA31A-CC7A-D77A-E040-BB89AD4346D2","latestVersionIndicator":"Yes","beginDate":"2009-06-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-09","modifiedBy":"ONEDATA","dateModified":"2009-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321323","version":"1","preferredName":"Prior Randomization","preferredDefinition":"Earlier in time or order.:The allocation of individuals to groups, e.g., for experimental and control regimens, by chance. (On-line Medical Dictionary)","longName":"C25629:C25196","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Randomization","conceptCode":"C25196","definition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-15E6-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BEDA31A-CC88-D77A-E040-BB89AD4346D2","latestVersionIndicator":"Yes","beginDate":"2009-06-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"IE_IEORRES_DXHIS","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Patient has histologically co","type":"Preferred Question Text","description":"Patient has histologically confirmed adenocarcinoma of the prostate diagnosed within 6 months prior to randomization","url":null,"context":"CTEP"},{"name":"CRF TEXT","type":"Alternate Question Text","description":"Histologically confirmed prostate adenocarcinoma diagnosis prior to registration","url":null,"context":"NRG"},{"name":"NRG_CRF_TEXT","type":"Alternate Question Text","description":"Histologically confirmed prostate adenocarcinoma diagnosis within 180 days prior to registration","url":null,"context":"NRG"},{"name":"NRG_CRF_TEXT 1","type":"Alternate Question Text","description":"Pathologically proven diagnosis of adenocarcinoma of prostate cancer within 180 days prior to registration","url":null,"context":"NRG"},{"name":"NRG_CRF_TEXT 2","type":"Alternate Question Text","description":"Pathologically proven diagnosis of prostate adenocarcinoma at any anatomical location,  including intraductal or ductal carcinoma, at anytime before registration","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma","url":null,"context":"NRG"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Participant has histologically confirmed adenocarcinoma of the prostate diagnosed within the last 9 months. (Participants on active surveillance may be enrolled if prostate biopsy was done within 9 months of enrollment and meets the histologic eligibility criteria.)","url":null,"context":"CCTG"}],"origin":"NCIC CRF:National Cancer Institute of Canada Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"6BEFBCF2-5600-0A34-E040-BB89AD437AB2","latestVersionIndicator":"Yes","beginDate":"2009-06-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-09","modifiedBy":"CLOHNES","dateModified":"2023-11-16","changeDescription":"Replaced Protocol Administration Ind-2 2018304v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"11/16/23 Added alt OID and AQT for CCTG ticket number CADSR0003085 cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}